Navigation Links
Ardea Biosciences Announces Changes to Research Management
Date:10/5/2007

on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of establishing a collaboration with a new non-profit foundation to leverage Ardea's early discovery assets for neglected diseases in developing countries, its goal of initiating Phase 1 clinical studies of RDEA119 and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... product choices to a manageable shortlist of bench and floor scales and terminals. ... fit best with the customer’s industry and application. , Side-by-side product comparisons ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... , , , ... a private biotechnology company discovering and developing innovative treatments for ... the department of physiology at the University of California, San ... has joined Solace,s scientific advisory board. , , ...
... , FLAGSTAFF, Ariz., July 24 ... New Zealand, Great Britain, Myanmar, the Philippines and Indonesia are meeting ... Woodlands Hotel to share research findings that will determine the future ... , On Sunday morning, Mayor Sara Presler will welcome ...
... , MADISON, N.J., July 24 Quest Diagnostics Incorporated ... testing, information and services, today announced that the U.S. Food and ... company,s Focus Diagnostics business for its test for detecting the 2009 ... A virus initially referred to as the swine flu virus. ...
Cached Biology Technology:Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control 2FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 2FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 3FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 4FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 5
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Stem cell research promises remedies to many devastating diseases ... disease to paralysis. Totipotent embryonic stem cells have great ... cells that can be used to restore malfunctioning or ... shown that pluripotent stem cells derived from adult bone ...
... as much at home walking four-legged on the ground as ... years ago with the same rare ability, a new study ... the agile walking and climbing skills of the lesser short-tailed ... absence of any ground-dwelling mammal competitors or predators, says an ...
... an enzyme in the brains of newborns suffering from ... brain damage that is a leading cause of cerebral ... Cincinnati Children,s Hospital Medical Center. Reporting their results ... show blocking the brain enzyme, tissue-type plasminogen activator (tPA), ...
Cached Biology News:Stem cell research: From molecular physiology to therapeutic applications 2Stem cell research: From molecular physiology to therapeutic applications 3Stem cell research: From molecular physiology to therapeutic applications 4Bizarre walking bat has ancient heritage 2Experimental treatment halts hypoxic-ischemic brain injury in newborns 2Experimental treatment halts hypoxic-ischemic brain injury in newborns 3
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
... Anti-M13 polyclonal antibody was derived from rabbit ... particles.Recombinant protein domains such as antibody fragments ... pIII and displayed on phage using phagemid-based ... utilized in the Ph.D. libraries. Anti-M13 pIII ...
... T4 Polynucleotide Kinase catalyzes the ... ATP to the 5-terminus of ... a 5-hydroxyl group. The enzyme, ... may be used to phosphorylate ...
... IVF are designed for human in vitro ... setup and operation, and convenience. Chamber, ... displayed on the control panel. Our signature ... by way of the thermal printer inside ...
Biology Products: